FDA Menopause Hormone Therapy Label Changes

The U.S. Food and Drug Administration wrote the sentence that defines this topic. It says it "has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs."
A labeling change is an edit to the paperwork that travels with a product. This page follows that edit for readers in Berkeley Heights who want the agency's words before anyone else's summary.
The second sentence names the edit
The same announcement from the U.S. Food and Drug Administration gets specific: "Specifically, risk statements related to cardiovascular disease, breast cancer and probable dementia were removed from the “boxed warning,” the agency’s most prominent safety-related warning."
Read the verb. The statements were removed from the boxed warning. The sentence says where they came out and does not say anything about the rest of the label.
Where each article picks up
The two child articles each start from a different part of that announcement.
- Boxed Warning Removal on Menopause Hormone Products reads the second sentence, the one about what left the boxed warning.
- Hot Flash Triggers, Duration and Treatment Choices covers the symptom side that sits beside the label story, as its title promises.
For the agency's general consumer page on the subject, see the FDA's menopause page. The Endocrine Society keeps its own menopause library entry, and holding the two side by side shows how each publisher words the same subject.
The detail worth rereading
Go back to the list inside the second sentence: cardiovascular disease, breast cancer and probable dementia. Those three named items, and the boxed warning they left, are the detail to check against the current label of any menopause hormone product you are offered.